This study is to determine the safety, pharmacokinetics/pharmacodynamics, and immunologic
impact of encapsulated rapamycin in patients with low risk prostate cancer under active
surveillance. There will be four groups of patients, each receiving a different dose of
rapamycin.
Phase:
Phase 1
Details
Lead Sponsor:
Rapamycin Holdings Inc. Rapamycin Holdings, Inc. dba Emtora Biosciences